A randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 4, 2002, Pages 286-303

  Castao, Gladys ^a   Más, Rosa ^b   Fernández, Lilia ^b   Illnait, José ^b   Hernández, Eric ^a   Fernández, Julio C ^b   Gámez, Rafael ^b   Gutiérrez, Carlos ^b   Alvarez, Estrella ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Adolescents; Cholesterol lowering drugs; Hypercholesterolemia; Lipid lowering therapy; Policosanol

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TABLET; TREATMENT OUTCOME;

EID: 0036260528     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80033-9     Document Type: Article

References (72)

1. Cardiovascular disease epidemiology. A journey from the past into the future
2. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
3. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III)
5. European and American recommendations for coronary heart disease prevention
6. An updated coronary risk profile: A statement for health professionals
7. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease
8. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
9. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
14. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary prevention of acute major coronary events in women and men with average cholesterol
15. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group
16. Lipoproteins in the progeny of young men with coronary artery disease: Children with increased risk
17. Factors affecting the relationship between childhood and adult cholesterol levels: The Muscatine Study
18. Parental history of cardiovascular disease as an indication for screening for lipoprotein abnormalities in children
19. National Cholesterol Education program: Report of the expert panel on blood cholesterol levels in children and adolescents
20. Dietary guidelines for children: U.S. recommendations
21. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: The Dietary Intervention Study in Children (DISC)
22. Prospective randomised trial in 1062 infants of diet low in saturated fat and cholesterol
23. Lipid lowering in the young
24. Nutrition and children: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
25. A rational approach to treating hypercholesterolaemia in children: Weighing the risks and benefits
26. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia
27. Choosing the right lipid-regulating agent: A guide to selection
28. "Fire and forget?" Pharmacological considerations in coronary care
29. Comparative tolerability of the HMG-CoA reductase inhibitors
30. Policosanol
31. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
32. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
33. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia
34. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
35. Effects of policosanol on primary hypercholesterolemia: A 3-year open-extension follow-up
36. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
37. A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
38. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant risk factors
39. Effect of policosanol on postmenopausal women with type II hypercholesterolemia
40. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function
41. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study
42. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
43. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
44. Effect of policosanol in older patients with type II hypercholesterolemia and high coronary risk
45. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women
46. Effects of policosanol on lipid profile and cardiac events in older hypercholesterolemic patients with coronary disease
47. Treatment of hypercholesterolemia in NIDDM with policosanol
48. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
49. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
50. Policosanol inhibits cholesterol biosynthesis and enhances low density, lipoprotein processing in cultured human fibroblasts
51. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats
52. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
53. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts
54. A 12-month study of policosanol oral toxicity in Sprague Dawley rats
55. Toxicity of policosanol in beagle dogs: One-year study
56. Teratogenic and reproductive studies of policosanol in the rat and rabbit
57. Carcinogenicity of policosanol in Sprague Dawley rats: A 24-month study
58. Carcinogenicity of policosanol in mice: An 18-month study
59. Multigeneration reproduction study of policosanol in rats
60. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats
61. Pharmacoepidemiologic study of policosanol
62. Policosanol: Results of a postmarketing surveillance study of 27,879 patients
63. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
64. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride
65. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
66. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints
67. Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis rates in man
68. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
69. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
70. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study
71. Evaluation of LDL oxide metabolites in children of high risk families